MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).

Q2 2026 Highlights^[1]

• Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY).

• Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY.

• Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income received from Regeneron.

• United States (U.S.) Food and Drug Administration (FDA) alignment on ProstACT Global Phase 3 study of TLX591-Tx in mCRPC^[2] to advance to Part 2 in the U.S.^[3]

• BiPASS^TM, patient enrollment nearing completion for study of Illuccix^® and Gozellix^® for initial prostate cancer diagnosis in the pre-biopsy setting^[4].

• Regeneron (NASDAQ: REGN) strategic collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies, initially focused on lung cancer.

• FY 2026 research and development (R&D) expenditure guidance updated to US$230 million to US$270 million, enabled by the Company’s strong commercial performance and the non-refundable payment of US$40 million received from Regeneron.

Q2 2026 Revenue

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA^[7] imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value.”

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q2 2026 highlights include:

• TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatamab tetraxetan): Achieved key regulatory milestone for ProstACT Global Phase 3 trial, with the FDA confirming that the safety data from Part 1 of the study of Telix’s lead prostate cancer therapy candidate is sufficient to enable progression of Part 2 in the U.S. The FDA and Telix also achieved alignment on the Part 2 clinical trial protocol, statistical analysis plan, and ongoing safety monitoring plan. Initiation of Part 2 in the U.S. remains subject to the FDA’s review of an Investigational New Drug (IND) amendment^[8]. Part 2 continues to enroll strongly in regions where recruitment is open including Australia, New Zealand, Canada, Türkiye, the United Kingdom, Singapore and South Korea and has also received regulatory approval to commence in China.

• TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA): OPTIMAL-PSMA study evaluating TLX597-Tx for mCRPC has recently completed patient enrollment of 120 patients^[9]. Building on initial findings of the OPTIMAL-PSMA study, the first patients have been dosed in the OPTIMAL-e Phase 2 study, evaluating TLX597-Tx for metastatic hormone sensitive prostate cancer^[10]. TLX597-Tx is a next generation small molecule PSMA-targeting prostate cancer radioligand therapy (RLT) candidate designed to improve efficacy and quality of life in earlier-stage metastatic prostate cancer.

• TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan): Dosed first patient in LUTEON^[11], a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC^[12]. LUTEON will evaluate the efficacy of TLX250-Tx compared with investigator’s choice of monotherapy consistent with standard of care. LUTEON forms part of Telix’s global development program^[13] for TLX250-Tx,  Part 1 is expected to enroll up to 40 patients.

• TLX101-Tx (¹³¹I-iodofalan): Enrolled first patient cohort in Part 1 (assessing safety and dose optimization) of IPAX BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma^[14]. The trial is open for enrollment in Australia, Austria, the Netherlands and Belgium, with approval being sought in additional jurisdictions. Completed patient enrollment in IPAX-2^[15], a Phase 1 study evaluating TLX101-Tx in patients with newly diagnosed glioblastoma, with no dose-limiting toxicities observed to date^[16].

Precision Medicine Business Unit

PSMA imaging portfolio:

Telix’s Precision Medicine business continues to expand its commercial reach and support broader patient access to PSMA-PET/CT imaging^[17]. Q2 2026 highlights include:

• Rapid enrollment of 338 patients in BiPASS™ Phase 3 study of Illuccix and Gozellix for the initial diagnosis of prostate cancer, integrating non-invasive ⁶⁸Ga-PSMA-11 PET imaging prior to biopsy. Building on the clinical foundation established by the PRIMARY^[18] and PRIMARY 2^[19] studies, BiPASS™ is intended to support regulatory submissions in major markets, including the U.S., Europe and Australia.

• Completed patient enrollment in Japan in Phase 3 registrational study of TLX591-Px (Illuccix)^[20]. Telix is preparing a New Drug Application (NDA) for submission in Japan, with clinical data from the Phase 3 local study intended to support the application. In parallel, Telix’s application for Conditional Approval is under review by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). If granted, Conditional Approval will enable an expedited NDA review process while the final study clinical dataset is prepared.

TLX101-Px, (Floretyrosine F 18 or 18F-FET) for brain cancer imaging:

• Submitted an IND application to the FDA for Pixclara^®, a Phase 3 registrational study for indication expansion for the diagnosis of brain metastases.

• The FDA has accepted Telix’s resubmitted NDA for Pixclara^®[21] and has granted a PDUFA^[22] goal date of September 11, 2026^[23].

• Telix’s Marketing Authorization Application (MAA) for Pixlumi^®21 in Europe has been validated and accepted for review^[24].

Zircaix^®21 (TLX250-Px, ⁸⁹Zr-DFO-girentuximab) for kidney cancer imaging:

• Telix continues to make good progress on its Biologics License Application (BLA) resubmission for Zircaix^®21 in the U.S. Final Chemistry, Manufacturing and Controls (CMC) documentation is nearing completion. Consistent with TLX250-Px’s Breakthrough Therapy designation, Telix has maintained regular consultation with the FDA and expects to resubmit the application shortly.

Telix Manufacturing Solutions (TMS): Expanded global operations

TMS continues to expand its global operations which are fundamental to Telix’s future growth, supporting supply chain resilience. Q2 2026 highlights include:

• Opened TMS North Melbourne, in partnership with the Melbourne Theranostic Innovation Centre (MTIC)^[25]. The purpose-built facility combines radiochemistry laboratories, clinical product manufacturing, patient dosing and imaging that aims to provide advanced clinical infrastructure and R&D capabilities to accelerate the development of targeted radiopharmaceuticals.

• TMS Brussels South successfully completed its first Good Manufacturing Practice (GMP) production run of a lutetium-based therapeutic candidate, representing a significant operational milestone and further validating the facility’s capabilities to support the manufacture of Telix’s next-generation therapeutics.

• Installed ARTMS’ QUANTM^® Irradiation System (QIS^®) at TMS Yokohama, expanding isotope production capabilities and enabling local Zirconium-89 (⁸⁹Zr) manufacturing to support Telix’s portfolio. The installation represents further progress in scaling the ARTMS network and advancing toward the Company’s target of 50 QIS^® installations globally by the end of 2026.

Corporate Updates

Telix entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies^[26]. The strategic partnership combines Telix’s radiopharmaceutical development, manufacturing and supply chain capabilities with Regeneron’s leading antibody discovery and development platforms, creating a framework to advance multiple novel oncology programs and further strengthen Telix’s position in Precision Medicine. On execution of the agreement, Telix has received an initial non-refundable payment from Regeneron of US$40 million.

Telix also completed a refinancing of its existing convertible bond structure, issuing US$600 million of new convertible bonds due 2031 and repurchasing all outstanding 2029 convertible bonds^[27]. The transaction extends debt maturities, enhances financial flexibility and further strengthens the Company’s capital structure, supporting the execution of Telix’s long-term growth strategy, including developing its late-stage therapeutics pipeline.

Three new Non-Executive Directors were appointed during the quarter as part of Telix’s Board expansion and succession planning. Effective May 11, 2026, David Gill, Maria Rivas, MD, and William Jellison^[28] joined the Board, further strengthening the Board’s clinical, commercial, financial and governance expertise, enhancing the Company’s capabilities as a dual-listed, commercial stage biopharmaceutical company.

FY 2026 guidance

• Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income from Regeneron.

• Revenue guidance reflects product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.

• Telix has updated FY 2026 R&D expenditure guidance to US$230 million to US$270 million, subject to achieving ongoing global clinical data outcomes and development milestones. The additional investment will support the advancement of high-value clinical programs beyond the Company’s original R&D forecast, including acceleration of the TLX597-Tx program and label expansion for Pixclara^®, and progression of the Regeneron strategic collaboration.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix^® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix^® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. FDA. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction. The Company’s late-stage therapeutic pipeline includes three assets in pivotal-stage trials – TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, complemented by a deep pipeline of next generation assets.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.  

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Latest leadership appointments reinforce Granicus’ commitment to “growth, innovation and customer success”
across Australia and New Zealand

MELBOURNE, Australia, July 21, 2026 /PRNewswire/ — Granicus, a leading provider of customer experience technologies and services for governments and destination organisations, today announced the appointment of Jonathan Usher as Managing Director for Australia and New Zealand, reinforcing the company’s commitment to the region and supporting its next phase of growth across Australia and New Zealand (ANZ).

Jonathan joins Granicus with more than 25 years of experience leading and scaling technology businesses across Australia and New Zealand. His background spans SaaS, cloud, cybersecurity and digital public services, with a strong track record of building scalable, customer-focused organisations and driving sustainable growth.

In his new role, Jonathan will lead Granicus’ ANZ business, working closely with customers, partners and employees to strengthen customer success, accelerate growth and help organisations deliver better experiences for citizens, visitors and communities.

“Jonathan brings an exceptional combination of leadership experience, commercial acumen and customer focus,” said G Masili, Chief Customer Officer at Granicus.” His understanding of technology, digital services and platform growth makes him ideally positioned to lead our Australia and New Zealand business. As demand continues to grow for modern, connected digital experiences, Jonathan’s experience will help us strengthen our support for customers across the region.”

Jonathan’s appointment forms part of a broader investment in Granicus’ Australia and New Zealand operations. In recent months, the company has also welcomed Julie Morton as Regional Sales Director and Pallavi Sathyanarayana as Regional Product Leader, further strengthening regional expertise across sales, product innovation and customer success.

Together, these appointments represent a significant investment in leadership capability and regional growth, creating a strong foundation for the next chapter of Granicus’ expansion across Australia and New Zealand.

“Throughout my career, I’ve been drawn to organisations that combine strong technology with a clear purpose,” said Jonathan Usher. “Granicus stands out because of the impact it helps customers create every day – helping governments and public sector organisations build stronger connections with the communities they serve. I’m excited to join the team and work alongside our customers and partners to help organisations across Australia and New Zealand deliver better experiences, strengthen engagement and create lasting value for their communities.”

The strengthened leadership team reflects Granicus’ long-term commitment to Australia and New Zealand and its ambition to support customers through the next generation of digital transformation, engagement and service delivery.

About Granicus:
Granicus is the global leader in digital experience technologies and services for the public sector, supporting more than 7,000 public sector organizations worldwide and managing more than 30 billion digital interactions each year. Through its Government Experience Cloud (GXC), Government Experience Agent (GXA), and Government Experience Insights (GXI) platforms, Granicus helps governments deliver trusted, accessible, and efficient services — at scale, and with accountability built in.

Granicus is proud to serve as a critical strategic partner to governments as they work to deliver equitable and secure government experiences. Granicus empowers stronger relationships between government and constituents across the US, UK, Australia, New Zealand, Canada, Latin America and the Caribbean. By simplifying interactions and communicating critical information, Granicus brings governments closer to the people they serve—driving meaningful change for communities around the globe. 

•  First patient dosed in Phase 3 LUTEON^[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
•  LUTEON is the first Phase 3 study of a CAIX^[2]-targeted radiopharmaceutical therapy in ccRCC

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (¹⁷⁷Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in patients with relapsed or recurrent ccRCC.

The patient was dosed at GenesisCare Murdoch (Western Australia), under the supervision of Dr. Aviral Singh.

Dr. Aviral Singh, Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Murdoch and Principal Investigator on the LUTEON trial, commented, “Dosing the first patient in the LUTEON study marks an important milestone in the development of potential new treatment options for patients with relapsed or recurrent clear cell renal cell carcinoma. Despite advances in care, outcomes remain poor for many patients, underscoring the need for innovative therapeutic approaches. This study will play a critical role in evaluating the safety, tolerability and efficacy of this investigational CAIX-targeted radiopharmaceutical for patients globally, and we look forward to helping advance the clinical evidence for this promising therapeutic candidate.”

Dr. David N. Cade, Telix Group Chief Medical Officer, added, “LUTEON represents the next stage in Telix’s global clinical development of TLX250-Tx and reflects our commitment to developing precision radiopharmaceuticals for patients with difficult-to-treat cancers. We aim to further evaluate the potential of TLX250-Tx that is designed to utilize the high prevalence of CAIX expression in ccRCC to deliver targeted radiation directly to tumor sites, while limiting exposure to healthy tissue.”

About TLX250-Tx

TLX250-Tx is a first-in-class CAIX-targeting rADC^[3] therapy candidate composed of a high-specificity monoclonal antibody chelated to the therapeutic radionuclide lutetium-177. CAIX is an attractive therapeutic target because it is expressed in more than 95% of ccRCC, while demonstrating limited expression in normal tissues, including kidney tissue^[4],[5].

LUTEON is being run under a Phase 3 protocol in Australia and forms part of Telix’s global development program for TLX250-Tx, which includes the separate Phase 2a LUTEON ATLAS study in the United States and Europe.

The LUTEON study utilizes Telix’s investigational PET^[6] imaging agent, TLX250-Px (Zircaix®^[7], zirconium-89 (⁸⁹Zr) girentuximab senvedoxam), to identify eligible patients with CAIX-positive tumors.

About clear cell Renal Cell Carcinoma

Renal Cell Carcinoma, RCC, is the most common form of kidney cancer, accounting for approximately 9 out of 10 diagnoses^[8]. Within this category, ccRCC is the most common and often the most aggressive subtype, representing about 85% of all RCC cases^[9] with up to 30% of patients presented with metastatic disease at diagnosis, which has a 20% 5-year survival rate^[10],[11]. 

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA). The Company’s late-stage therapeutic pipeline includes three assets in pivotal-stage trials – TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, complemented by a deep pipeline of next generation assets. TLX250-Tx and TLX250-Px have not received a marketing authorization in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

DUBAI, UAE, July 21, 2026 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, today announced the launch of RLUSD Hold & Earn, a limited-time rewards event featuring the Ripple USD (RLUSD) stablecoin. From now until August 19, 2026, eligible users can make the most of their RLUSD portfolios on Bybit whether they choose to hold, trade, or compete.

RLUSD’s market capitalization has grown to over $1.5 billion in 2026, with expanding institutional adoption including integrations with exchanges, major banks, and financial institutions.

RLUSD Hold & Earn allows eligible users to earn daily rewards on RLUSD held in their Bybit account, with no staking or lock-up required. Hold longer, earn more. The longer users continue to hold RLUSD, the more rewards they may become eligible for in future campaigns. Eligible users can start at a minimum of 1 RLUSD. Balances are snapshotted 24 times daily, and rewards are calculated based on effective daily holdings, with eligible balances capped at 5,000,000 RLUSD per user. 

The exclusive Hold and Earn event includes a loyalty multiplier based on continuous holding duration, rewarding users who maintain their positions over time. Rewards are distributed as commercial incentives and do not constitute interest, yield, or investment returns on RLUSD itself.

For traders, Bybit is cutting trading costs for the RLUSDUSDT spot pair for a limited time, cutting maker fees from 0.10% to 0% and taker fees from 0.10% to 0.04%.

The third segment, Bybit’s exclusive RLUSD Trading Competition, adds a 50,000 RLUSD prize pool, giving eligible traders the opportunity to compete for additional rewards through RLUSD spot trading activity during the promotional period.

Institutional clients are eligible for Hold & Earn but are excluded from the Trading Competition.

RLUSD is a USD-backed stablecoin issued by Ripple. Natively issued on XRP Ledger, Ethereum, and other blockchains, Ripple USD is fully backed by a segregated reserve of cash and cash equivalents and redeemable 1:1 for US dollars. As a regulated, reserve-backed digital asset, RLUSD offers the price stability of traditional cash in onchain form.

Terms and conditions apply. For more details on eligibility and potential restrictions, users may visit: RLUSD Hold & Earn: Earn Up to 7% APR and Enjoy 0-Maker Fee Spot Trading

#Bybit / #NewFinancialPlatform 

About Bybit

Bybit is The New Financial Platform.

We believe every person should have access to every financial opportunity on earth. That’s why we’re building the first intelligent platform that connects anyone, anywhere to the world’s finance.

Trusted by more than 80 million users worldwide, Bybit brings together investing, trading, payments, and wealth-building in a single secure and intelligent ecosystem. Through the combination of AI-powered technology, deep global liquidity, robust security, and transparent operations, Bybit makes global finance more accessible, efficient, and empowering for everyone.

Built for everyone. Powered by intelligence. Open to the world.

Learn more at Bybit.com

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

A calmer category of AI hardware, not a phone, not a wearable, not another app, designed to stay close, understand context, and help people follow through on what matters.

NEW YORK, July 20, 2026 /PRNewswire/ — Prompt engineering has become unpaid labor. Notifications compete for attention people no longer have to give. Every new AI tool asks users to open another app, manage another workflow, and organize their own thinking before the tool can help. Nooklab, an AI hardware company building for the global market, today shared its vision for an alternative: a low-distraction AI screen designed to help people remember, organize, and act without managing another tool.

Nooklab is defining a new category: a physical AI screen that stays close to daily life, captures voice and context, and turns scattered information, ideas, and commitments into actions AI can carry forward. Rather than asking people to organize their own thinking, the screen is designed to understand what matters, surface it at the right time, and help move it toward completion.

“AI shouldn’t ask you to become its operator,” said Raymond Zhao, Founder and CEO of Nooklab. “It should meet you where you already are, and help you follow through on what you already care about.”

Zhao brings deep experience across consumer electronics and global product development. He previously held product leadership roles at OPPO, OnePlus, Anker, and ByteDance, working on foldable phones, AI glasses, and other emerging hardware categories.

Sign-ups for early access open in October at nooklab.ai. Nooklab plans to reveal more details about its first product later this year, including the final product name, industrial design, hardware form factor, display technology, and full feature set.

About Nooklab

Founded in 2026, Nooklab is a global AI hardware company exploring a better relationship between people and AI. Its team brings experience from ByteDance, Anker, OnePlus, OPPO, and Temu, and the company recently closed its seed round with a pre-A round in preparation. Nooklab is developing low-distraction AI screens that stay close to daily life, understand context, and support people without requiring complicated workflows, prompt engineering, or constant tool management.

Nooklab Website: www.nooklab.ai 

TAIPEI, July 20, 2026 /PRNewswire/ — Jazz Hipster today unveiled its next-generation wireless audio platform strategy during HIGH END Vienna 2026, highlighting a broader move from standalone product development toward scalable audio ecosystem architecture for the streaming era.

Jazz Hipster Product Manager Ben Hsu said the new direction reflects how the premium audio market is evolving beyond traditional product categories. Streaming speakers, active speakers, soundbars, desktop audio systems, and multi-room products are increasingly converging into connected audio ecosystems where wireless transmission, streaming integration, low-latency synchronization, and software architecture are becoming as critical as acoustic performance itself.

Rather than treating wireless connectivity as an added feature, Hsu said Jazz Hipster is positioning wireless audio transmission as part of the core system architecture.

According to Hsu, Jazz Hipster’s latest development framework combines Dolby Atmos system design, WiFi 6 low-latency wireless audio, Hi-Res wireless transmission, DSP processing, streaming service integration, and scalable speaker expansion into a unified platform architecture designed for next-generation home entertainment and premium audio products.

Hsu said the new platform strategy is intended to support a wide range of future product categories, including wireless bookshelf speakers, Dolby Atmos systems, streaming amplifiers, wireless audio hubs, active speakers, and installation audio products.

A Shift Toward Connected Audio Ecosystems

According to Hsu, the audio industry is entering a new phase where consumers increasingly expect audio systems to work seamlessly across music streaming, TV audio, desktop entertainment, gaming, and multi-room listening environments.

As a result, audio brands are facing a growing challenge: how to develop scalable product families that can share the same core architecture while adapting to different use cases, price segments, and industrial designs.

Hsu believes this shift is fundamentally changing how premium audio systems are developed.

Instead of building isolated hardware products, future development will increasingly depend on reusable system architectures capable of supporting streaming services, wireless synchronization, DSP-based acoustic tuning, HDMI integration, and high-resolution playback within a unified ecosystem.

Hi-Res Wireless Audio as a Core Technology Direction

Hsu said a central part of Jazz Hipster’s platform strategy is high-resolution, low-latency wireless audio over WiFi.

The architecture supports wireless audio transmission ranging from 48kHz / 24bit to 192kHz / 24bit, depending on system configuration and application requirements. The wireless host-and-receiver structure is designed to support both stereo streaming products and multi-channel immersive audio systems.

Hsu sees Hi-Res wireless transmission as a key enabling technology for the next generation of premium audio products, particularly as wireless speakers and active audio systems continue moving into higher-performance market segments traditionally dominated by wired systems.

Expanding Dolby Atmos Beyond Traditional Soundbar Formats

Hsu also discussed broader development plans around wireless Dolby Atmos ecosystem integration.

He said Dolby Atmos applications are moving beyond fixed soundbar configurations toward more flexible wireless speaker architectures, where soundbars, satellite speakers, subwoofers, streaming speakers, and audio hubs can be developed from a shared platform logic.

By combining scalable multi-channel system architecture with streaming integration and wireless synchronization technologies, brands can develop multiple product tiers and ecosystem configurations while maintaining consistency in acoustic tuning, latency control, and user experience.

Streaming Audio and Home Entertainment Are Converging

Hsu further noted that streaming audio and home entertainment are becoming increasingly interconnected.

Modern consumers no longer view music streaming, TV audio, gaming audio, and desktop entertainment as separate product categories. Instead, users increasingly expect a single audio system to support multiple entertainment scenarios while maintaining premium sound quality and seamless connectivity.

To address this shift, Jazz Hipster’s platform architecture integrates technologies including HDMI eARC, AirPlay, Chromecast, Spotify Connect, Bluetooth 5.4, DSP processing, and wireless multi-room synchronization into a unified development framework.

Hsu said this approach will allow global audio brands to accelerate product development while simplifying system integration across future product families.

From Product ODM to Platform-Based Audio Development

Hsu said the new strategy also reflects a broader evolution in Jazz Hipster’s role as an ODM partner.

Rather than focusing solely on individual hardware projects, Hsu said Jazz Hipster is now investing in reusable audio system architectures that can scale across multiple product categories and market segments.

Future roadmap directions include Dolby Atmos systems, wireless speakers, streaming amplifiers, wireless audio hubs, active speakers, installation audio products, and PoE-based audio solutions.

According to Hsu, future competition in premium audio will depend less on standalone hardware specifications alone and more on ecosystem integration, wireless synchronization, streaming compatibility, acoustic optimization, and scalable platform development.

About Jazz Hipster

Jazz Hipster is a professional premium audio ODM partner with more than 40 years of experience in audio R&D and manufacturing. The company specializes in acoustic engineering, DSP integration, streaming audio, wireless audio platforms, Dolby Atmos systems, active speaker development, and precision manufacturing for global audio brands.

Original article: https://jazzhipster.com/next-gen-dolby-atmos-wireless-audio-ecosystem/